Literature DB >> 27314429

Management of Neurologic Manifestations in Patients with Liver Disease.

José M Ferro1,2, Pedro Viana3, Patrícia Santos4.   

Abstract

OPINION STATEMENT: Liver disease, both in its acute and chronic forms, can be associated with a wide spectrum of neurologic manifestations, both central and peripheral, ranging in severity from subclinical changes to neurocritical conditions. Neurologists are frequently consulted to participate in their management. In this review, we present an overview of management strategies for patients with hepatic disease whose clinical course is complicated by neurologic manifestations. Type A hepatic encephalopathy (HE), which occurs in acute liver failure, is a neurologic emergency, and multiple measures should be taken to prevent and treat cerebral edema. In Type C HE, which occurs in chronic liver disease, management should be aimed at correcting precipitant factors and hyperammonemia. There is an increasing spectrum of drug treatments available to minimize ammonia toxicity. Acquired hepatocerebral degeneration is a rare complication of the chronic form of HE, with typical clinical and brain MRI findings, whose most effective treatment is liver transplantation. Epilepsy is frequent and of multifactorial cause in patients with hepatic disease, and careful considerations should be made regarding choice of the appropriate anti-epileptic drugs. Several mechanisms increase the risk of stroke in hepatic disease, but many of the drugs used to treat and prevent stroke are contraindicated in severe hepatic failure. Hepatitis C infection increases the risk of ischemic stroke. Hemorrhagic stroke is more frequent in patients with liver disease of alcoholic etiology. Viral hepatitis is associated with a wide range of immune-mediated complications, mostly in the peripheral nervous system, which respond to different types of immunomodulatory treatment. Several drugs used to treat hepatic disease, such as the classical and the new direct-acting antivirals, may have neurologic complications which in some cases preclude its continued use.

Entities:  

Keywords:  Acquired hepatocerebral degeneration; Acute liver failure; Bromocriptine; Chronic liver disease; Epilepsy; Hepatic encephalopathy; Liver cirrhosis; Peripheral neuropathy; Portosystemic encephalopathy; Stroke; Viral hepatitis

Year:  2016        PMID: 27314429     DOI: 10.1007/s11940-016-0419-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  87 in total

Review 1.  Cryoglobulinemia Vasculitis.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; David Saadoun
Journal:  Am J Med       Date:  2015-03-30       Impact factor: 4.965

2.  Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration.

Authors:  Hee K Park; Seung M Kim; Choong G Choi; Myoung C Lee; Sun J Chung
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

3.  Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.

Authors:  Michele Malaguarnera; Marco Vacante; Massimo Motta; Maria Giordano; Giulia Malaguarnera; Rita Bella; Giuseppe Nunnari; Liborio Rampello; Giovanni Pennisi
Journal:  Metab Brain Dis       Date:  2011-08-26       Impact factor: 3.584

Review 4.  Neurologic complications of hepatic viruses.

Authors:  Johann Sellner; Israel Steiner
Journal:  Handb Clin Neurol       Date:  2014

5.  Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients.

Authors:  Elisa Maffeo; Anna Montuschi; Guido Stura; Maria Teresa Giordana
Journal:  Neurol Sci       Date:  2013-05-28       Impact factor: 3.307

Review 6.  Recent insights into the pathogenesis of hepatic encephalopathy and treatments.

Authors:  Jonathan P Sturgeon; Debbie L Shawcross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-01       Impact factor: 3.869

7.  Characteristics of 20 Patients with Autochthonous Acute Hepatitis E in Hokkaido, Japan: First Report of Bilateral Facial Palsy Following the Infection with Genotype 4 Hepatitis E Virus.

Authors:  Yasuyuki Yazaki; Kenji Sugawara; Mitsunori Honda; Hiroshi Ohnishi; Shigeo Nagashima; Masaharu Takahashi; Hiroaki Okamoto
Journal:  Tohoku J Exp Med       Date:  2015-08       Impact factor: 1.848

8.  Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.

Authors:  Macarena Simón-Talero; Rita García-Martínez; Maria Torrens; Salvador Augustin; Susana Gómez; Gustavo Pereira; Mónica Guevara; Pere Ginés; Germán Soriano; Eva Román; Jordi Sánchez-Delgado; Roser Ferrer; Juan C Nieto; Pilar Sunyé; Inma Fuentes; Rafael Esteban; Juan Córdoba
Journal:  J Hepatol       Date:  2013-07-19       Impact factor: 25.083

9.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  3 in total

Review 1.  Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature.

Authors:  D Marques-da-Silva; V Dos Reis Ferreira; M Monticelli; P Janeiro; P A Videira; P Witters; J Jaeken; D Cassiman
Journal:  J Inherit Metab Dis       Date:  2017-01-20       Impact factor: 4.982

2.  Prevalence of cerebrovascular diseases that can cause hemorrhagic stroke in liver transplantation recipients: a 6-year comparative study with 24,681 healthy adults.

Authors:  Yeongu Chung; Seungjoo Lee; Jung Cheol Park; Jae Sung Ahn; Eun Ji Moon; Jung Won Park; Wonhyoung Park
Journal:  Neurol Sci       Date:  2020-10-30       Impact factor: 3.307

Review 3.  Cardiac and Pulmonary Vascular Risk Stratification in Liver Transplantation.

Authors:  Blessing Aghaulor; Lisa B VanWagner
Journal:  Clin Liver Dis       Date:  2020-10-26       Impact factor: 6.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.